US WorldMeds Buys Solstice Neurosciences
US WorldMeds LLC has acquired Solstice Neurosciences Inc., a Malvern, Pa.-based drug company whose first product is a botulinum toxin type B. The deal is valued at $35 million. Solstice Neurosciences had raised around $90 million in VC funding, plus another $35 million in venture debt. Equity backers included Highland Capital Management, Thomas, McNerney & Partners, Investor Growth Capital, Morgan Stanley Venture Partners and Oxford Bioscience Partners.
16 August 2010•3 mins read
